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Abstract 
Background: Malawi experienced prolonged use of sulfadoxine/pyrimethamine (SP) as the front-line anti-malarial 
drug, with early replacement of chloroquine and delayed introduction of artemisinin-based combination therapy. 
Extended use of SP, and its continued application in pregnancy is impacting the genomic variation of the Plasmodium 
falciparum population.
Methods: Whole genome sequence data of P. falciparum isolates covering 2 years of transmission within Malawi, 
alongside global datasets, were used. More than 745,000 SNPs were identified, and differences in allele frequencies 
between countries assessed, as well as genetic regions under positive selection determined.
Results: Positive selection signals were identified within dhps, dhfr and gch1, all components of the parasite folate 
pathway associated with SP resistance. Sitting predominantly on a dhfr triple mutation background, a novel copy 
number increase of ~twofold was identified in the gch1 promoter. This copy number was almost fixed (96.8% fre-
quency) in Malawi samples, but found at less than 45% frequency in other African populations, and distinct from a 
whole gene duplication previously reported in Southeast Asian parasites.
Conclusions: SP resistance selection pressures have been retained in the Malawian population, with known resist-
ance dhfr mutations at fixation, complemented by a novel gch1 promoter duplication. The effects of the duplication 
on the fitness costs of SP variants and resistance need to be elucidated.
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malawi suffers a heavy burden of endemic falciparum 
malaria with year-round transmission that peaks dur-
ing the long rainy season from early December to May 
[1]. Malaria still accounts for 40% of hospitalizations in 
children under 5  years of age and 30% of all outpatient 
visits [2]. The malaria mortality rate is 63 per 100,000 
population, and amongst the highest in East Africa [3] 
despite the roll out of control measures, such as insecti-
cide-treated bed nets (ITNs), intensive indoor residual 
spraying (IRS), and artemisinin-based combination ther-
apy (ACT) [2]. As one of the first African countries to 
switch from chloroquine to sulfadoxine/pyrimethamine 
(SP) in 1993, and the last to switch from SP to ACT in 
2007, Malawi stands out from the rest of Africa in having 
a significantly prolonged exposure to SP [4]. Whilst this 
meant the reduced frequency of chloroquine resistance 
alleles in the Plasmodium population [5], the same can-
not currently be said for SP resistance [6]. Resistance to 
SP is thought to be a cumulative process whereby muta-
tions are successively acquired in both the dhfr (S108N, 
N51I, C59R, then I164L) and dhps (A437G then K540E) 
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genes. These dhps and dhfr polymorphisms persist at 
high frequency in the Malawian Plasmodium population 
despite exposure to SP being reduced. Retention of these 
variants may be due in part to the use of SP in intermit-
tent preventive treatment for pregnant women (IPTp) or 
a lower than expected fitness cost associated with these 
variants [6]. The scaling up of the distribution of ACT 
and IPTp contributed to a 36% drop in the mortality rate 
between 2004 and 2014 for children under 5 years of age, 
to an estimated 85 deaths per 1000 live births [2]. How-
ever, the control efforts could be derailed by the use of 
SP in IPTp strategies in sites where parasites resistant to 
SP persist, as well as any future emergence and spread of 
ACT-resistant parasites (as seen in Southeast Asia).
Genetic variation in Plasmodium falciparum is cen-
tral to the parasite’s survival and can potentially under-
mine malaria control interventions. The evolutionary 
process enables parasite populations to select for vari-
ants that rapidly overcome host immune responses and 
anti-malarial drugs to establish persistent infections and 
increase transmission. Therefore, surveying evolutionar-
ily driven genetic changes in P. falciparum and investigat-
ing parasite responses to anti-malarial interventions are 
crucial to efforts to reduce the malaria burden. Where 
regions are working towards pre-elimination, longitudi-
nal samples are required to monitor parasite transmis-
sion dynamics and the efficacy of interventions to control 
malaria.
Previous work in a rural Malawian P. falciparum pop-
ulation in the Chikwawa district in a single ‘baseline’ 
season (n =  69, December 2010 to July 2011) identified 
several genes encoding merozoite invasion ligands as 
being retained in the population due to balancing selec-
tion [7]. This type of selection actively maintains multi-
ple alleles in the gene pool of a population. Further, by 
comparing the Malawian P. falciparum population to 
others in Africa and Southeast Asia, signals of recent 
positive selection were identified at known drug targets 
(e.g., dhps, crt and mdr1), metabolic enzymes (e.g., gch1), 
and in several invasion ligands (e.g., msp3.8, trap and 
ama1) [7]. Initial analysis provided evidence of popula-
tion divergence presumably driven by drug selection on 
crt, dhps and mdr1 genes, and reflects the adaptation of 
parasite populations to local drug pressure, especially SP. 
The dhps (sulfadoxine target) and dhfr (pyrimethamine) 
genes are on the folate biosynthesis pathway of P. falci-
parum, and in Southeast Asian populations a copy num-
ber variant in gch1 (first gene in pathway) is thought to be 
associated with SP resistance and its persistence [8].
The initial work in Malawi [7] was followed up by 
including additional ‘baseline’ season samples (n  =  29, 
total n = 98) and comparing the genetic diversity in 122 
isolates collected in the subsequent 2012 dry and wet 
seasons in the Chikwawa and Zomba districts, located 
100 km apart. These regions are sentinel sites in Malawi, 
chosen for intensive anti-malarial intervention involving 
ACT, ITNs and IRS. The aim was to identify changes in 
allele frequency within individual, intra- and inter-season 
(wet and dry seasons) and identify regions under selec-
tion pressure. The findings demonstrate limited variation 
between the Malawian sub-populations over time and the 
impact of prolonged exposure of parasites to SP. Particu-
larly, fixation of several known SP resistance SNPs and a 
novel copy number increase of the gch1 promoter region 
were identified. Cross-population analysis revealed selec-
tive pressure for chloroquine resistance in non-Malawian 
populations. These populations have experienced pro-
longed use of chloroquine. Overall, the findings support 
the use of parasite and population genetic approaches to 
monitor transmission and the adaptation to drug pres-
sure, and thereby inform the timing and type of inter-
ventions to be applied. Existing surveillance could be 
enhanced with rapid, field-based, genomic tests which 
genotype the gch1 promoter region as a proxy for SP 
resistance in an African setting.
Methods
Study sites and sample collection
Whole blood samples were collected from October 2010 
to November 2012 from children aged 5–28  months 
recruited in an ongoing ACTia[abbrev?] study within 
the high-transmission Chikwawa and Zomba regions in 
Malawi [7]. All individuals recruited had clinical falcipa-
rum malaria and received artemether/lumefantrine (AL) 
or dihydroartemisinin/piperaquine (DHA) treatment 
post-collection. Written informed consent was obtained 
from a parent or guardian of each child with the ethics 
committees of the University of Malawi’s College of Med-
icine and the Liverpool School of Tropical Medicine both 
approving the study.
Whole‑genome sequencing and quality control
Human DNA contamination was reduced through leuko-
cyte-depletion of the blood samples using CF11 column 
filtration [9]. Purified DNA samples (n = 220) containing 
less than 30% human DNA were sequenced at the Sanger 
Institute using Illumina HiSeq2500 technology, with a 
minimum of 76-base, paired-end, fragment sizes. All 
short reads were mapped to the 3D7 reference genome 
(version 3.0) using bwa-mem [10]. SNPs and small indels 
were called using samtools and bcf/vcftools with default 
settings [10]. Only those variants with quality scores 
in excess of 30 (indicating an error rate less than one 
per 1000  bp) and with minimum coverage of ten were 
retained [10]. Genotypes at SNP positions were called 
using ratios of coverage and heterozygous calls were 
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converted to the majority genotype on a 70:30 cover-
age ratio or greater [7, 11, 12]. SNPs were excluded from 
analysis if they had more than 5% mixed or missing geno-
type calls, or they were positioned within non-unique 
regions, sub-telomeric regions or within the hypervari-
able var, rifin and stevor gene families.
Raw sequencing data were also mapped for previously 
published P. falciparum strains (3D7, HB3, DD2, 7G8, 
GB4) [11] and isolates from East Africa (Kenya, Tan-
zania, n  =  33), West Africa (Burkina Faso, The Gam-
bia, Ghana, Guinea, Mali, Nigeria, n  =  430), Central 
Africa [Democratic Republic of Congo (DRC), n = 56], 
South America (Colombia, Peru, n  =  21), South Asia 
(Bangladesh, n  =  54) and Southeast Asia (Cambodia, 
Laos, Myanmar, Papua New Guinea, Thailand, Viet-
nam, n = 1187) [7, 11–14] using the pipeline described 
above. Public accession numbers for raw sequence data 
analysed are contained in SRA studies ERP000190 and 
ERP000199, as well as being accessible from the Pf3k 
project website (https://www.malariagen.net/projects/
pf3k). In total, the isolate dataset contains 745,913 high 
quality SNPs; 245,215 SNPs have no missing genotype 
calls, 77.1% within genes and 9.1% have a minor allele 
frequency greater than 1%.
Statistical analysis
Population stratification in the isolates was investigated 
using a principal component analysis (PCA) of the pair-
wise SNP distances between samples. This approach 
identified distinct African, Asian and South American 
clusters, with a further African-only investigation iden-
tifying West, Central and East African clusters. Differ-
ences in allele frequencies at each SNP were estimated 
using fixation indexes (FST), with genes ranked by their 
maximum scores [15]. Tajima’s D [16] was implemented 
to identify genomic regions under balancing selection, 
with a score greater than two suggesting strong balancing 
selection. Scores were calculated for each gene contain-
ing at least four SNPs. All SNP-based analyses were per-
formed using base R functions. Copy number variation 
in isolates and strains was analysed with DELLY using 
default settings [17].
Extended haplotype homozogysity (EHH)-based selec-
tion analyses, intra-population iHS and inter-population 
XP-EHH, were performed using selscan [18], using the 
default minor allele frequency and EHH truncation val-
ues of 0.05. Pair-wise country XP-EHH analyses used 
Malawi as the reference group, and both iHS and XP-
EHH values were normalized genome-wide. P values 
for iHS and XP-EHH estimates were calculated using a 
Gaussian approximation. A significance threshold of 
P  <  0.00006 was established for both iHS (>4) and XP-
EHH (>6), using a simulation approach.
Results
Malawi sub‑population analysis over time and location
Potential stratification within the Malawi dataset, across 
season, year and location of collection, was explored 
before consideration of shared signals. Of the 220 para-
site isolates collected in this study, 85.9% were from 
the Chikwawa region whilst only 14.1% were from the 
Zomba region. Season-wise 43.2% were collected in a wet 
season, 56.8% in a dry season, across three years (2010 
5.0%, 2011 39.5%, 2012 55.5%). Allele frequency differ-
ences between the location (median FST 0.003, max. 0.11) 
and year (median FST 0.004, max. 0.07) sub-populations 
were small. Within and between the seasons and location, 
the number of SNP differences was similar (~9400 SNPs) 
(see Additional file  1: Table S1). Twenty-six SNPs have 
an FST value greater than 0.15 for within-Malawi year, 
location and season-based sub-populations. Seven of 
these are intergenic and four within ‘conserved unknown’ 
genes (see Additional file  1: Table S2). The remaining 
15 SNPs are within putative or known genes, including 
surfin14.1 (max. FST 0.172), heat shock protein 90 (max. 
FST 0.166) and the immune evasion antigen PfEMP1 
(max. FST 0.157) [19]. Notably, all top pair-wise FST val-
ues above 0.15 were from season-based comparisons. No 
major differences were detected in allele frequency for 
known drug resistance mutations (see Additional file  1: 
Table S3).
Selection within the combined Malawian parasite 
sub‑populations
Given the absence of strong stratification between the 
sub-populations, the Malawian datasets were combined 
to identify selection signals within population. Signa-
tures of potential recent positive selection were identified 
within 13 genes (iHS  >  4). Five of these genes are cur-
rently uncharacterized, and three within close proxim-
ity to genes of known function and established selection 
sites (see Fig. 1; Additional file 1: Table S4). For example, 
the PF3D7_1223400 signal (iHS: −4.948) is within 2 kbp 
of gch1, and loci were identified within 60  kbp of dhps 
and 8.5 kbp of dhfr, both members of the P. falciparum 
folate pathway [20]. Selection in these genomic regions 
within Malawi has been suggested previously [11] and 
relates to selective pressure due to use of SP.
Additional allele selection signals are present within 
the erythrocyte invasion critical protein ama1 [21] (iHS: 
5.129, 5.017) and the sporozoite surface protein trap (iHS: 
5.366, 5.209), both representing hits that have been sug-
gested previously [22, 23]. Non-reference allele selection 
loci were also found within Plasmepsin X (iHS: 4.686), 
which has a role in ookinete invasion [24]. In contrast, 
reference allele selection was identified centred on four 
loci within TRS85 (iHS: −4.502), RRF1 (iHS: −4.376) and 
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PArt/TrpA-3 (iHS: −5.604, −5.396). Three genes show 
potential balancing signals within the Malawian P. falci-
parum population (Tajima’s D > 2; see Additional file 1: 
Table S5). These are ama1, required for erythrocyte inva-
sion [25], surf8.2, a group A SURFIN protein not found to 
be expressed post-invasion [26] but associated with sus-
ceptibility to pyrimethamine (inhibits folic acid metabo-
lism via dhfr) [27], and a conserved unknown protein 
(PF3D7_0710200) within chromosome 7. The ama1 
locus has both balancing and positive selection, suggest-
ing positive selection for one specific haplotype alongside 
the retention of multiple others. Such complex selection 
has previously been identified as differing between ama1 
domains [27, 28].
Malawi within a global context
Parasite genetic diversity within Malawi was further 
contextualized within a global setting. A PCA approach 
identified distinct African, Asian and South American 
clusters, as previously reported using large SNP datasets 
[7, 11, 12, 14, 29]. Within the African-only analysis, dis-
tinct West, Central and East African clusters were also 
distinguished, and Malawi was separated from Tanzania 
and Kenya. (see Additional file 2: Figure S1).
Pair-wise FST values were calculated genome-wide for 
Malawi against each country with at least 14 samples. The 
median FST values per region per SNP were then estimated 
to identify those that contained Malawi-unique variants 
(see Table 1). The top hits included the dhps K540E causal 
mutation, likely reflecting the prevalence of SP resistance 
in Malawi and other East African populations considered, 
compared to elsewhere (Table  2; Additional file  1: Table 
S6). Of the remaining top hits, the study identified the P47 
and P230 genes that share roles in gametocyte fertility [30], 
P48/45 reflecting differences in mosquito vectors [30], and 
PF3D7_0913900 a putative arginine-tRNA ligase. When 
considering drug-resistant candidate polymorphism, crt 
mutations (K76T, Q271E, N326S, I356T) were absent in 
Malawi, reflecting early withdrawal of chloroquine com-
pared to other African countries (see Table 2; Additional 
file  1: Table S6). K76T and Q271E mutations are near 
fixed in Asia, and known to have undergone ‘hard’ selec-
tive sweeps [31]. Compared to other African populations, 
Malawi has a higher frequency of dhfr triple mutant haplo-
types (N51I/C59R/S108N) and dhfr⁄dhps quintuple mutant 
genotypes (dhfr N51I/C59R/S108N haplotype and dhps 
A437G/K540E haplotype). The dhps S436A mutation was 
at high frequency in West Africa, and almost absent in 
Malawi. The contributing dhfr quadruple mutation (I164L) 
and dhfr⁄dhps sextuple mutant genotypes (dhfr⁄dhps quin-
tuple mutant genotype and dhfr I164L) were only present 
in Asia. In Malawi, the dhps A581G mutation, which has 
been shown to reduce the effectiveness of SP preventive 
therapy [32] was present at low frequency, leading to the 
presence of an alternative dhfr⁄dhps sextuple genotype 
(dhfr⁄dhps quintuple genotype and dhfr I164L). In the 
Malawian population, no variants of the kelch13 gene, pre-
viously described in Southeast Asia to be associated with 
artemisinin resistance [33], were identified. All alternative 
alleles in kelch13 are present at low frequencies, the maxi-
mum at 0.091 for K189T, and reflect previous SNPs fre-
quencies for the rest of Africa [34].
The XP-EHH method was used to identify regions 
under selection in the Malawi population compared 
to others. Positive values suggest relative selection in 
Malawi, whilst negative values suggest selection in non-
Malawi (see Additional file 2: Figure S2; Additional file 1: 
Table S7). 31 genes (|XP-EHH|  >  6) were identified, of 
which 18 are uncharacterized and 14 appear against only 
one other country. The most striking signals were within 
PF3D7_1223400 and PF3D7_1223500, both uncharacter-
ized but within 2 kbp of gch1, and indicate relative selec-
tion within the Malawian population when compared 
to Burkina Faso, the DRC, The Gambia, Ghana, Guinea, 
Fig. 1 Whole genome integrated haplotype score (iHS) for the combined Malawian parasite population. Red dotted lines indicate threshold of 
normalized iHS scores greater than four
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Kenya, and Mali (see Additional file  1: Table S7; Addi-
tional file 2: Figure S2). Strong shared negative XP-EHH 
scores were also present within acs8, the uncharacter-
ized PF3D7_1421100 and the SP resistance gene dhps. 
Strong positive signals, suggestive of selection in the non-
Malawian populations, were present within msp10, trap 
and three genes directly downstream of crt (cg1, glp3, 
cg2).
Adaptive copy number selection in the gch1 promoter
Given the hypothesized role for copy number variation 
(CNV) in gch1-mediated SP resistance [35] and signals 
of selection observed, potential CNVs at this locus were 
investigated. Evidence of a promoter duplication was 
found (genomic region 973,804–974,240 bp; see Fig. 2) in 
almost all Malawian samples (n = 213, 96.8%; see Table 2; 
Additional file  1: Table S6). Similar promoter duplica-
tions were found in samples from Ghana (n = 59, 29.2%), 
Guinea (n = 43, 45.3%), DRC (n = 25, 44.6%), The Gam-
bia (n = 5, 9.1%), and Asia (n = 5, < 0.4%). In contrast, the 
whole gch1 gene duplication [8] was predicted in samples 
from Thailand (n = 29, 13.8%), Cambodia (n = 23, 4.4%), 
Vietnam (n = 20, 10.7%), Ghana (n = 10, 5%), Myanmar 
(n = 7, 7.4%), and Bangladesh (n = 6, 11.1%) (see Fig. 2; 
Table 1 Differences in allele frequencies between Malawi and other populations (based on pairwise FST scores)
Values are the median FST values for each regional population. In italics are regional medians above 0.5
Gene ID Position Gene Other East Africa DRC West Africa South Asia Southeast Asia South America
PF3D7_0810800 549,993 dhps 0.053 0.873 0.974 0.118 0.415 0.628
PF3D7_0209000 375,427 P230 0.023 0.035 0.689 0.722 0.569 0.775
PF3D7_1016500 663,199 PHISTc 0.023 0.077 0.504 0.463 0.174 0.775
PF3D7_0913900 596,674 Arginine-tRNA ligase 0.017 0.014 0.769 0.665 0.719 0.518
PF3D7_1339700 1,595,988 Conserved unknown 0.013 0.017 0.323 0.555 0.731 0.213
PF3D7_1032100 1,293,621 dcp1 0.021 0.132 0.709 0.578 0.659 0.485
PF3D7_1223500 958,593 Conserved unknown (near 
gch1)
0.093 0.285 0.535 0.668 0.667 0.668
PF3D7_1361800 2,481,275 Conserved unknown 0.02 0.019 0.533 0.630 0.606 0.665
PF3D7_0708500 385,921 hsp86 0.292 0.297 0.428 0.542 0.625 0.016
PF3D7_1346800 1,880,114 P47 0.055 0.26 0.434 0.590 0.590 0.590
PF3D7_0113000 489,337 garp 0.024 0.064 0.562 0.587 0.478 0.104
PF3D7_0716700 730,051 Conserved unknown 0.034 0.079 0.366 0.533 0.567 0.567
PF3D7_0307900 350,293 Conserved unknown 0.016 0.169 0.524 0.267 0.487 0.524
PF3D7_1248700 1,997,660 Conserved unknown 0.131 0.211 0.457 0.426 0.457 0.459
PF3D7_1223400 942,564 Phospholipid-transporting 
ATPase (near gch1)
0.172 0.237 0.380 0.444 0.444 0.444
PF3D7_1223300 938,341 gyrA (near gch1) 0.146 0.237 0.374 0.444 0.308 0.444
PF3D7_1223400 941,821 Phospholipid-transporting 
ATPase (near gch1)
0.171 0.216 0.381 0.442 0.442 0.442
PF3D7_1426700 1,036,865 pepc 0.022 0.001 0.429 0.251 0.419 0.430
PF3D7_0215300 629,060 acs8 0.174 0.104 0.402 0.393 0.426 0.132
PF3D7_1346700 1,876,606 P48/45 0.120 0.042 0.324 0.426 0.402 0.220
PF3D7_0615900 665,589 Conserved unknown 0.002 0.261 0.37 0.311 0.343 0.373
PF3D7_1433900 1,362,042 Putative protein kinase 0.051 0.012 0.233 0.368 0.340 0.368
PF3D7_0811600 586,054 Conserved unknown 0.003 0.065 0.340 0.358 0.304 0.358
PF3D7_0724900 1,056,801 Putative kinesin-19 0.010 0.099 0.220 0.358 0.344 0.358
PF3D7_1414200 564,437 Conserved unknown 0.003 0.083 0.278 0.333 0.333 0.333
PF3D7_1021700 883,159 Conserved unknown 0.027 0.201 0.317 0.300 0.331 0.331
PF3D7_0627800 1,115,191 Putative acetyl-CoA syn-
thetase
0.042 0.325 0.325 0.325 0.325 0.325
PF3D7_1218300 718,254 Ap2mu 0.029 0.312 0.309 0.312 0.312 0.312
PF3D7_1223100 928,407 PKAr 0.231 0.306 0.306 0.306 0.306 0.306
PF3D7_1222600 911,963 AP2-G 0.218 0.274 0.304 0.304 0.297 0.304
PF3D7_1223300 935,411 gyrA (near gch1) 0.213 0.306 0.306 0.306 0.306 0.306
PF3D7_0932800 1,306,240 Conserved unknown 0.063 0.274 0.304 0.304 0.297 0.304
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Table 2; Additional file 1: Table S6). The gene duplication 
appears predominantly on the background of dhfr triple 
mutant haplotype in West Africa (79.2%) and a quad-
ruple mutant haplotype in Southeast Asia (80.3%) and 
South Asia (50.0%) (see Table 3). The promoter duplica-
tion is seemingly not linked to the dhfr I164L quadruple 
mutation and sits predominantly on a triple mutant hap-
lotype background in Malawi (99.1%), DRC (87.9%) and 
West Africa (85.8%) (see Fig.  3). In these populations, 
the haplotype background of dhps S436A, A437G and 
K540E appears less important with a number of mutation 
combinations present (Table 3). The exception is Malawi 
where the promoter sits on a predominantly dhps 
A437G/K540E haplotype background, leading to the high 
frequency of quintuple mutant genotypes.  
Coverage analysis of the P. falciparum reference 
strains 3D7, HB3, DD2, 7G8, and GB4 identified no 
upstream promoter duplication. Previously identi-
fied whole gene duplications in 3D7, 7G8, DD2, and 
GB4, and the absence of duplication in HB3, were con-
firmed [36] (see Additional file  2: Figure S4). 38 SNPs 
(eight non-synonymous) were identified across the 
Table 2 Drug resistance allele frequencies
DRC Democratic Republic of Congo
a Any two of N51I, C59R or S108N
b N51I, C59R & S108N
c Triple dhfr mutant haplotype with I164L
d dhfr N51I/C59R/S108N haplotype + dhps A437G/K540E haplotype
SNP Malawi Other East Africa DRC West Africa South Asia South East Asia South America
Sample size 220 33 56 430 54 1133 21
dhps
 S436A 0.005 0.061 0.107 0.505 0.509 0.313 0
 A437G 0.998 0.894 0.902 0.735 0.843 0.971 0.286
 K540E 0.995 0.894 0.063 0.014 0.778 0.477 0.190
 A581G 0.027 0.091 0.027 0.002 0.156 0.407 0.238
dhfr
 N51I 0.991 0.909 0.982 0.658 0.471 0.897 0.381
 C59R 0.991 0.939 0.821 0.745 0.972 0.996 0
 S108N 1 1 1 0.781 1 0.998 0.952
 I164L 0 0 0 0 0.167 0.438 0
 Double dhfr mutanta 1 1 1 0.728 0.982 0.995 0.381
 Triple dhfr mutantb 0.977 0.848 0.750 0.563 0.392 0.887 0
 Quadruple dhfr Mutantc 0 0 0 0 0.167 0.438 0
dhfr-dhps
 Quintuple genotyped 0.968 0.788 0.036 0.007 0.278 0.421 0
 Quintuple + dhfr I164L 0 0 0 0 0.130 0.266 0
 Quintuple + dhps A581G 0.027 0.091 0.027 0 0.111 0.198 0
crt
 K76T 0 0.485 0.661 0.416 0.889 0.960 1.000
 Q271E 0 0.485 0.643 0.430 0.907 0.935 0
 N326S 0 0 0 0.002 0.241 0.630 0
 I356T 0 0 0.196 0.140 0.833 0.652 0
kelch13
 K189T 0.091 0.061 0.196 0.502 0.130 0.007 0.714
 K189 N 0.005 0 0 0.026 0 0 0
 Y493H 0 0 0 0 0 0.044 0
 C580Y 0 0 0 0 0 0.224 0
gch1
 Promoter duplication 0.968 0 0.446 0.251 0.037 0.003 0
 Whole gene duplication 0 0 0.020 0.023 0.111 0.076 0
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gch1 coding region using the global dataset, all with 
non-reference allele frequencies (<4%), except a SNP in 
South America (position 974,633, 28.3%). In the gch1 
promoter region there were 11 SNPs occurring only in 
African populations, all at low frequency (<4%), except 
for one polymorphism, which was almost always found 
on a non-duplication background (position 974,046: 
East Africa 10.0%, DRC 18.3%, West Africa 18.5%). The 
overall low levels of nucleotide variation and sequence 
homogeneity support the argument that gch1 copy 
number variants, rather than associated coding SNPs, 
are targeted by selection. Examination of the EHH 
revealed differences in linkage disequilibrium (LD) 
between continents and within Africa (see Fig. 4; Addi-
tional file 2: Figure S2). When considering African pop-
ulations, there is evidence in non-Malawian populations 
of near symmetrical decays of EHH to a level close to 
zero within 25 kb. Malawi LD extends much wider and 
is consistent with a sweep around the promoter duplica-
tion (see Fig. 4).
To determine whether the gch1 promoter duplication 
was under relative positive selection in the DRC, Ghana 
and Guinea, a sub-population was applied XP-EHH anal-
ysis, where those with the duplication were compared 
to those without. This approach identified no significant 
differential sub-population selection in either the DRC, 
Ghana or Guinea (|XP-EHH|  <  4), although there are 
near-significant positive selection signals for the duplica-
tion-positive sub-populations in Ghana and Guinea (see 
Additional file 2: Figure S3). This contrasts with Malawi, 
where the duplication appears to be under active selec-
tion, potentially reflecting differences in SP usage (see 
Fig. 1; Additional file 2: Figure S2).
Discussion
Malaria surveillance is crucial to informing and support-
ing disease prevention, control and elimination strate-
gies. Access to technological advances and their reduced 
costs mean monitoring approaches involving genomic 
data are being implemented within malaria programmes 
Fig. 2 Coverage plots displaying gch1 whole gene and promoter duplications. The Malawi (ERR237436) and Ghanaian (ERR045593) samples 
represent promoter duplications (upstream of the gch1 coding region) of approximately twofold, the Thailand sample (ERR248939) represents 
whole gene duplication (green region) and the Laos sample (ERR216496) represents no duplication. Neighbouring non-gch1 genes are displayed as 
the grey regions. Coverage is scaled against the median coverage (indicated by the dashed red line) for chromosome 12 and calculated for 100 bp 
windows, with an offset of 25 bp
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[7, 12, 14]. To inform such programmes, genomic differ-
ences were investigated in Malawian P. falciparum para-
sites from two regions across multiple seasons. No major 
differences were observed between the two regional or 
temporal sub-populations, potentially due to small sam-
ple sizes, a narrow two-year study period, the removal of 
a minority of SNPs with a high frequency of missing or 
heterozygous genotypes, and study regions that are only 
100 km apart with high human migration between them.
Because of the effects of control measures on Plasmo-
dium genomes, signals of selection and differences in 
allele frequencies were also investigated across Malawi 
parasites and compared with those from global datasets. 
Signals in drug resistance-associated genes, and surface-
associated proteins that are exposed to the host immune 
system were detected, including previously described 
selection in msp10, trap and ama1 [7, 23]. Antibod-
ies against the pre-erythrocyte TRAP and erythrocyte 
stages MSP10 and AMA1 proteins have been detected 
in anti-malarial-acquired immunity individuals living in 
malaria-endemic areas [37, 38]. Vaccines using TRAP, 
AMA1 and MSP proteins (e.g., MSP1 and MSP3) are 
being tested with promising results [39]; as such the 
MSP10 protein may represent a viable vaccine candidate.
Consistent with previous reports, crt mutations (K76T, 
Q271E, N326S, I356T) were absent from Malawi [40, 41]. 
Neighbouring countries (as well as others in Africa) that 
did not switch away from chloroquine as early as Malawi 
continue to report higher levels of crt mutations. This 
observation has led to a setting likened to a Malawian 
island of chloroquine drug sensitivity in a sea of resist-
ance [41]. Three genes, cg1, glp3 and cg6, immediately 
downstream of the crt gene, displayed high relative posi-
tive selection in multiple non-Malawian populations, 
consistent with hard selective sweeps [31]. In contrast, SP 
resistance-associated dhfr and dhps alleles are retained 
at high frequencies in Malawi. Compared to other Afri-
can populations there is a significantly higher level of 
Table 3 Co-association frequencies of dhfr mutations and gch1 duplications
Frequencies greater than 0.2 are shown in italics
a dhfr mutant haplotypes: double—any two of dhfr N51I, C59R or S108N; triple—dhfr N51I, C59R and S108N; quadruple—dhfr triple mutant haplotype with I164L; 
DRC Democratic Republic of Congo
b dhps double mutant haplotypes consist of dhps A437G and K540E
dhfr mutantsa gch1 duplica‑
tion
dhps mutantsb Malawi Other East 
Africa
DRC West Africa South Asia Southeast Asia South America
None None None 0 0 0 0.067 0 0.002 0.048
None None Single 0 0 0 0.095 0 0 0
Single None None 0 0 0 0.002 0.019 0.002 0.524
Single None Single 0 0 0 0.040 0 0 0.048
Double None None 0 0.030 0.018 0.030 0.019 0.031 0.143
Double None Single 0 0 0.071 0.112 0.019 0.028 0
Double None Double 0.005 0.121 0 0.002 0.278 0.021 0.143
Double Promoter None 0 0 0 0.002 0 0 0
Double Promoter Single 0 0 0.054 0.028 0 0 0
Double Promoter Double 0.009 0 0 0 0 0 0
Double Gene Single 0 0 0 0.005 0 0 0
Double Gene Double 0 0 0 0 0.037 0.001 0
Triple None None 0 0.061 0.036 0.086 0.019 0.078 0
Triple None Single 0 0 0.393 0.328 0.056 0.190 0.048
Triple None Double 0.032 0.788 0.036 0.005 0.389 0.185 0.048
Triple Promoter None 0 0 0.036 0.012 0 0 0
Triple Promoter Single 0 0 0.304 0.160 0 0 0
Triple Promoter Double 0.950 0 0.054 0.009 0 0 0
Triple Gene Single 0 0 0 0.014 0 0.007 0
Triple Gene Double 0 0 0 0 0 0.006 0
Quadruple None None 0 0 0 0 0.019 0.004 0
Quadruple None Single 0 0 0 0 0.019 0.144 0
Quadruple None Double 0 0 0 0 0.093 0.244 0
Quadruple Gene Single 0 0 0 0 0 0.014 0
Quadruple Gene Double 0 0 0 0 0.037 0.042 0
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both the dhfr C59R mutation and the quintuple dhfr⁄dhps 
mutant genotypes. These frequencies are consistent with 
previous analyses highlighting the pan-African distribu-
tion of the dhfr triple mutant haplotypes in contrast to 
the East–West African differences in distribution of the 
A437G and K540E dhps variants [42, 43]. The SNP-based 
work is consistent with the results from microsatellite-
based studies, considering the dynamics of strong selec-
tion for mutations conferring SP resistance, including 
support for the observation of the independent origin of 
sulfadoxine-resistant alleles across a number of regions 
[42, 44, 45]. Together, these observations reflect the early 
decline in chloroquine usage and early introduction and 
prolonged use of SP in Malawi when compared to other 
African populations.
In almost all Malawian samples (96.8%), a novel dupli-
cation was identified in the promoter of the gch1 gene 
(973,804–974,240  bp), a member of the folate pathway 
that includes targets for sulfadoxine and pyrimethamine. 
This duplication was also detected in other parasites, 
particularly from West Africa and the DRC, but is near-
absent in Asia. Whole gene duplications have previously 
been detected in Thailand and Cambodia [33] and were 
detected in this dataset. Positive selection signals are pre-
sent across the gch1 region in Malawi, with relative selec-
tion in Malawi compared to other African populations 
where the promoter duplication is also present. Further, 
samples with the duplication were not found to be under 
relative selection in the DRC, Ghana or Guinea. Together, 
the strong evidence of selection for this promoter dupli-
cation in Malawi supports its role as being advantageous 
for P. falciparum parasites in regions with high SP use, 
particularly where there is a higher frequency of resist-
ance-associated dhfr and possibly dhps variants.
The function of the promoter duplication remains 
to be established. It is possible that both promoter and 
whole gene duplications increase gch1 expression in vivo 
thereby reducing the fitness cost associated with dhfr 
and dhps variants, which convey resistance to SP. In sil-
ico, functional predictions for the promoter duplication 
Fig. 3 Relationship between dfhr mutations and gch1 copy numbers. Plasmodium falciparum parasites with DELLY-predicted gch1 promoter dupli-
cation across Africa exist almost exclusively on a dhfr triple mutant background, whilst predicted whole gene duplication in South East Asia is linked 
to the dhfr ‘quadruple mutant’
Fig. 4 EHH plots for multiple populations, centred on a SNP within 
gch1 (chromosome 12, position 974,659)
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identified multiple TATA, TATAA and TGTAA PfTBP 
binding motifs [46]. If this duplication acts to reduce the 
fitness cost of other SP resistance-associated variants, its 
presence may suggest a more persistent form of resist-
ance which further surveillance will need to confirm. 
Ongoing fieldwork in Malawi will allow to survey the 
parasite population during longer periods and to detect 
genomic changes following the introduction of ACT. Fur-
ther work should also consider the genomic landscape 
within other African countries to determine the fre-
quency of the gch1 duplication and other variants associ-
ated with SP resistance.
Conclusion
This study reports the persistence of genetic variants 
associated with SP and chloroquine resistance within the 
P. falciparum population in Malawi, despite withdrawal 
of these anti-malarials from front-line use. Signals of pos-
itive selection were also identified, which suggest reten-
tion of these resistance-associated variants, as well as 
various life stage-specific surface antigens. Investigation 
of gch1 copy number variation identified the near fixation 
of a specific 436 bp promoter duplication within Malawi, 
present in other African countries but absent from Asian 
populations. It is most likely that this promoter dupli-
cation acts in a similar fashion to the whole gene dupli-
cation present in Asian populations, although further 
experimental work is required to elucidate any functional 
impact.
Authors’ contributions
AC, SC, HO, and TGC conceived and designed the study; MM, ATRJ, CJS, CR, NS, 
JM, KSP, AT, and HO performed laboratory experiments, contributed biological 
samples, sequencing, epidemiological or phenotypic data; MR, EDB and TGC 
performed the statistical analysis; DPK led the sequencing effort. MR, SC, HO, 
and TGC wrote/drafted and finalized the manuscript with contributions from 
all other authors. All authors read and approved the final manuscript.
Author details
1 Faculty of Infectious and Tropical Diseases, London School of Hygiene 
and Tropical Medicine, London, UK. 2 Department of Physiology, College 
of Medicine, University of Malawi, Blantyre, Malawi. 3 Centre for Medical Para-
sitology, University of Copenhagen, Copenhagen, Denmark. 4 Centre for Sta-
tistics and Applications of University of Lisbon, Lisbon, Portugal. 5 Wellcome 
Trust Sanger Institute, Hinxton, UK. 6 Liverpool School of Tropical Medicine, 
Pembroke Place, Liverpool, UK. 7 Malawi-Liverpool-Wellcome Trust Clinical 
Research Programme, College of Medicine, University of Malawi, Blantyre, 
Malawi. 8 School of Public Health and Family Medicine, College of Medicine, 
University of Malawi, Blantyre, Malawi. 9 Faculty of Epidemiology and Popula-
tion Health, London School of Hygiene and Tropical Medicine, London, UK. 
Additional files
Additional file 1. Additional tables.
Additional file 2. Additional figures.
Acknowledgements
We thank the parents, guardians and children who participated in this 
study, and the technical, clinical and nursing staff for assistance. The Medical 
Research Council UK funded eMedLab computing resource was used for data 
analysis.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Public accession numbers for raw sequence data analysed are contained in 
SRA studies ERP000190 and ERP000199, as well as being accessible from the 
Pf3k project website (https://www.malariagen.net/projects/pf3k).
Ethics approval and consent to participate
Written informed consent was obtained from a parent or guardian of each 
child with the ethics committees of the University of Malawi’s College of Medi-
cine and the Liverpool School of Tropical Medicine both approving the study.
Funding
MR is funded by the Biotechnology and Biological Sciences Research Council 
(Grant Number BB/J014567/1). This work was supported by the Malaria 
Capacity Development Consortium (to HO), which is funded by The Wellcome 
Trust (Grant Number WT084289MA). JM was supported by a Wellcome Trust 
fellowship (Grant Number 080964). TGC is supported by the Medical Research 
Council UK (GRANT No. MR/K000551/1, MR/M01360X/1, MR/N010469/1, MC_
PC_15103). SC is funded by the Medical Research Council UK (GRANT No. MR/
M01360X/1, MC_PC_15103). The Wellcome Trust provides core support to the 
Sanger Institute (Grant Number 077012/Z/05/Z, 098051), the Resource Centre 
for Genomic Epidemiology of Malaria (Grant Number 090770/Z/09/Z), and The 
Malawi-Liverpool-Wellcome Trust Programme.
Received: 29 September 2016   Accepted: 23 November 2016
References
 1. The demographic and health surveys program. Malawi malaria indicator 
survey. 2014. https://dhsprogram.com/pubs/pdf/MIS18/MIS18.pdf.
 2. President’s malaria initiative. The President’s malaria initiative A decade 
of progress. 2016. https://www.pmi.gov/docs/default-source/default-
document-library/pmi-reports/pmi-tenth-annual-report-congress.pdf.
 3. WHO. World Health Statistics 2015. Geneva: World Health Organization; 
2015.
 4. Flegg JA, Metcalf CJE, Gharbi M, Venkatesan M, Shewchuk T, Hopkins 
Sibley C, et al. Trends in antimalarial drug use in Africa. Am J Trop Med 
Hyg. 2013;89:857–65.
 5. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe 
PN, et al. Reemergence of chloroquine-sensitive Plasmodium falcipa-
rum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 
2003;187:1870–5.
 6. Artimovich E, Schneider K, Taylor TE, Kublin JG, Dzinjalamala FK, Escalante 
AA, et al. Persistence of sulfadoxine-pyrimethamine resistance despite 
reduction of drug pressure in Malawi. J Infect Dis. 2015;212:694–701.
 7. Ocholla H, Preston MD, Mipando M, Jensen AT, Campino S, MacIn-
nis B, et al. Whole-genome scans provide evidence of adaptive 
evolution in Malawian Plasmodium falciparum isolates. J Infect Dis. 
2014;210:1991–2000.
 8. Nair S, Miller B, Barends M, Jaidee A, Patel J, Mayxay M, et al. Adap-
tive copy number evolution in malaria parasites. PLoS Genet. 
2008;4:e1000243.
 9. Auburn S, Marfurt J, Maslen G, Campino S, Ruano Rubio V, Manske M, 
et al. Effective preparation of Plasmodium vivax field isolates for high-
throughput whole genome sequencing. PLoS ONE. 2013;8:e53160.
 10. Li H, Durbin R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics. 2009;25:1754–60.
Page 11 of 11Ravenhall et al. Malar J  (2016) 15:575 
 11. Samad H, Coll F, Preston MD, Ocholla H, Fairhurst RM, Clark TG. 
Imputation-based population genetics analysis of Plasmodium falciparum 
malaria parasites. PLoS Genet. 2015;11:e1005131.
 12. Preston MD, Campino S, Assefa SA, Echeverry DF, Ocholla H, Amambua-
Ngwa A, et al. A barcode of organellar genome polymorphisms identifies 
the geographic origin of Plasmodium falciparum strains. Nat Commun. 
2014;5:4052.
 13. Auburn S, Campino S, Miotto O, Djimde AA, Zongo I, Manske M, et al. 
Characterization of within-host Plasmodium falciparum diversity using 
next-generation sequence data. PLoS ONE. 2012;7:e32891.
 14. Neher RA, Amato R, Miotto O, Woodrow CJ, Almagro-Garcia J, Sinha I, 
Campino S, Mead D, Drury E, Kekre M, Sanders M. Genomic epidemiology 
of artemisinin resistant malaria. eLife. 2016;5:e08714.
 15. Nei M. Analysis of gene diversity in subdivided populations. Proc Natl 
Acad Sci USA. 1973;70:3321–3.
 16. Tajima F. Statistical method for testing the neutral mutation hypothesis 
by DNA polymorphism. Genetics. 1989;123:585–95.
 17. Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: struc-
tural variant discovery by integrated paired-end and split-read analysis. 
Bioinformatics. 2012;28:i333–9.
 18. Szpiech ZA, Hernandez RD. selscan: an efficient multithreaded program 
to perform EHH-based scans for positive selection. Mol Biol Evol. 
2014;31:2824–7.
 19. Pasternak ND, Dzikowski R. PfEMP1: an antigen that plays a key role in the 
pathogenicity and immune evasion of the malaria parasite Plasmodium 
falciparum. Int J Biochem Cell Biol. 2009;41:1463–6.
 20. Hyde JE. Exploring the folate pathway in Plasmodium falciparum. Acta 
Trop. 2005;94:191–206.
 21. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, Crabb BS, et al. Api-
cal membrane antigen 1 plays a central role in erythrocyte invasion by 
Plasmodium species. Mol Microbiol. 2000;38:706–18.
 22. Mu J, Myers RA, Jiang H, Liu S, Ricklefs S, Waisberg M, et al. Plasmodium 
falciparum genome-wide scans for positive selection, recombination hot 
spots and resistance to antimalarial drugs. Nat Genet. 2010;42:268–71.
 23. Amambua-Ngwa A, Park DJ, Volkman SK, Barnes KG, Bei AK, Lukens AK, 
et al. SNP genotyping identifies new signatures of selection in a deep 
sample of West African Plasmodium falciparum malaria parasites. Mol Biol 
Evol. 2012;29:3249–53.
 24. Li F, Bounkeua V, Pettersen K, Vinetz JM. Plasmodium falciparum ookinete 
expression of plasmepsin VII and plasmepsin X. Malar J. 2016;15:111.
 25. Srinivasan P, Yasgar A, Luci DK, Beatty WL, Hu X, Andersen J, et al. Disrupt-
ing malaria parasite AMA1–RON2 interaction with a small molecule 
prevents erythrocyte invasion. Nat Commun. 2013;4:2261.
 26. Mphande FA, Ribacke U, Kaneko O, Kironde F, Winter G, Wahlgren M. 
SURFIN4.1, a schizont-merozoite associated protein in the SURFIN family 
of Plasmodium falciparum. Malar J. 2008;7:116.
 27. Borrmann S, Straimer J, Mwai L, Abdi A, Rippert A, Okombo J, et al. 
Genome-wide screen identifies new candidate genes associated with 
artemisinin susceptibility in Plasmodium falciparum in Kenya. Sci Rep. 
2013;3:3318.
 28. Gunasekera AM, Wickramarachchi T, Neafsey DE, Ganguli I, Perera L, Pre-
maratne PH, et al. Genetic diversity and selection at the Plasmodium vivax 
Apical Membrane Antigen-1 (PvAMA-1) locus in a Sri Lankan population. 
Mol Biol Evol. 2007;24:939–47.
 29. Manske M, Miotto O, Campino S, Auburn S, Almagro-Garcia J, Maslen G, 
et al. Analysis of Plasmodium falciparum diversity in natural infections by 
deep sequencing. Nature. 2012;487:375–9.
 30. van Dijk MR, van Schaijk BCL, Khan SM, van Dooren MW, Ramesar J, 
Kaczanowski S, et al. Three members of the 6-cys protein family of Plas-
modium play a role in gamete fertility. PLoS Pathog. 2010;6:e1000853.
 31. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, et al. Genetic 
diversity and chloroquine selective sweeps in Plasmodium falciparum. 
Nature. 2002;418:320–3.
 32. Gutman J, Kalilani L, Taylor S, Zhou Z, Wiegand RE, Thwai KL, et al. The 
A581G mutation in the gene encoding Plasmodium falciparum dihydrop-
teroate synthetase reduces the effectiveness of sulfadoxine-pyrimeth-
amine preventive therapy in Malawian pregnant women. J Infect Dis. 
2015;211:1997–2005.
 33. Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, 
et al. A worldwide map of Plasmodium falciparum K13-propeller polymor-
phisms. N Engl J Med. 2016;374:2453–64.
 34. Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, et al. 
Polymorphisms in K13 and falcipain-2 associated with artemisinin resist-
ance are not prevalent in Plasmodium falciparum isolated from Ugandan 
children. PLoS ONE. 2014;9:e105690.
 35. Heinberg A, Siu E, Stern C, Lawrence EA, Ferdig MT, Deitsch KW, et al. 
Direct evidence for the adaptive role of copy number variation on 
antifolate susceptibility in Plasmodium falciparum. Mol Microbiol. 
2013;88:702–12.
 36. Sepúlveda N, Campino SG, Assefa SA, Sutherland CJ, Pain A, Clark TG. A 
Poisson hierarchical modelling approach to detecting copy number vari-
ation in sequence coverage data. BMC Genom. 2013;14:128.
 37. Maskus DJ, Bethke S, Seidel M, Kapelski S, Addai-Mensah O, Boes A, et al. 
Isolation, production and characterization of fully human monoclo-
nal antibodies directed to Plasmodium falciparum MSP10. Malar J. 
2015;14:276.
 38. Noland GS, Hendel-Paterson B, Min XM, Moormann AM, Vulule JM, 
Narum DL, et al. Low prevalence of antibodies to pre erythrocytic but 
not blood-stage Plasmodium falciparum antigens in an area of unstable 
malaria transmission compared to prevalence in an area of stable malaria 
transmission. Infect Immun. 2008;76:5721–8.
 39. Schwartz L, Brown GV, Genton B, Moorthy VS. A review of malaria vac-
cine clinical fold projects based on the WHO rainbow table. Malar J. 
2012;11:11.
 40. Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE, Plowe 
CV. Return of chloroquine-susceptible falciparum malaria in Malawi was a 
re expansion of diverse susceptible parasites. J Infect Dis. 2010;202:801–8.
 41. Bridges DJ, Molyneux M, Nkhoma S. Low level genotypic chloroquine 
resistance near Malawi’s northern border with Tanzania. Trop Med Int 
Health. 2009;14:1093–6.
 42. Pearce RJ, Pota H, Evehe MS, Bâ EH, Mombo-Ngoma G, Malisa AL, et al. 
Multiple origins and regional dispersal of resistance dhps in African 
Plasmodium falciparum malaria. PLoS Med. 2009;6:e1000055.
 43. Naidoo I, Roper C. Mapping ‘partially resistant’, ‘fully resistant’, and ‘super 
resistant’ malaria. Trends Parasitol. 2013;29:505–15.
 44. McCollum AM, Schneider KA, Griffing SM, Zhou Z, Kariuki S, ter-Kuile F, 
et al. Differences in selective pressure on dhps and dhfr drug resistant 
mutations in western Kenya. Malar J. 2012;11:77.
 45. Vinayak S, Alam MT, Mixson-Hayden T, McCollum AM, Sem R, Shah NK, 
et al. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. 
PLoS Pathog. 2010;6:e1000830.
 46. Ruvalcaba-Salazara OK, del Carmen Ramírez-Estudilloa M, Montiel-Con-
dadoa D, Recillas-Targab F, Vargasa M, Hernández-Rivasa R. Recombinant 
and native Plasmodium falciparum TATA-binding-protein binds to a 
specific TATA box element in promoter regions. Mol Biochem Parasitol. 
2005;140:183–96.
